Jianfeng Chen

Jianfeng Chen

Auto-generated profile, based on publicly available information

Jianfeng Chen

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2026 in Science
Verified
Journal Article
Closed access
KCKyung Serk Cho
Kyung Serk Cho
YLYunhe Liu
Yunhe Liu
GPGuangsheng Pei
Guangsheng Pei
JCJianfeng Chen
Jianfeng Chen
YDYibo Dai
Yibo Dai
LWLinghua Wang
Linghua Wang
Tertiary lymphoid structures (TLSs) are critical regulators of antitumor immunity, yet their spatial organization, maturation, and clinical relevance remain incompletely defined across cancers. We analyzed spatial transcriptomics spanning 12 cancer types to construct a pan-cancer TLS atlas and characterized TLS spatial architecture and maturation states. TLS maturation was accompanied by coordinated remodeling of distinct niche cell populations and distance-dependent gradients in tumor programs, orthogonally supported by ultrahigh-plex single-cell spatial profiling. To enable scalable TLS profiling, we trained an artificial intelligence framework that predicts TLS maturation states directly from hematoxylin and eosin–stained images and evaluated it across TCGA and independent therapy cohorts. We further derived a maturation-aware composite score capturing intratumoral TLS state composition, which robustly stratifies patients across cancer and treatment contexts, outperforming conventional TLS metrics.

1 August 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
AKAnne Knisely
Anne Knisely
YDYibo Dai
Yibo Dai
GBGraham L. Barlow
Graham L. Barlow
SLSanghoon Lee
Sanghoon Lee
BLBarrett Lawson
Barrett Lawson
AJAmir A. Jazaeri
Amir A. Jazaeri
Purpose: Minimal residual disease (MRD) after first-line treatment of advanced-stage ovarian cancer remains a long-standing barrier to cure. We investigated the prognostic and translational value of MRD detection by second-look laparoscopy (SLL) and ctDNA at the completion of first-line therapy. Experimental Design: Patients with high-grade epithelial ovarian cancer who had a complete clinical response to first-line therapy and underwent SLL and plasma collection for ctDNA were included. Progression-free survival (PFS) and overall survival (OS) were estimated based on MRD and clinicopathologic status. Spatial transcriptomics (GeoMx and Visium) and proteomics (CODEX) profiling were performed on serial samples from select patients. Results: Forty of 95 (42.1%) patients had surgically detected MRD, which was associated with worse PFS (median PFS 7.4 vs. 23.8 months; P < 0.001) and OS (median OS 33.9 vs. not reached; P < 0.001). SLL positivity was an independent negative prognostic factor for OS (HR, 4.40; 95% confidence interval, 1.37–14.21; P = 0.013) in multivariable analysis. Among 44 patients who underwent SLL and had ctDNA testing, 34% (15/44) were ctDNA-positive, which was associated with worse PFS (6.4 vs. 28.1 months; P < 0.001) and OS (32.4 months vs. not reached; P = 0.008). We demonstrated the feasibility of spatial multiomics in studying MRD and their ability to provide hypothesis-generating observations, implicating the upregulation of the hypoxia signaling pathway, expression of multiple druggable targets (CDK6, GLS, MSLN, ERBB2), and immune exclusion in MRD lesions. Conclusions: Approximately half of patients in clinical remission after first-line therapy have assessable MRD, which can inform prognosis, therapeutic target discovery, and clinical trials.

1 October 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
SMStefan Maksimovic
Stefan Maksimovic
NBNina C. Boscolo
Nina C. Boscolo
LPLudovica La Posta
Ludovica La Posta
SBSergio Barrios
Sergio Barrios
Mohammad Jad MoussaMohammad Jad Moussa
Mohammad Jad Moussa
EDEleonora Dondossola
Eleonora Dondossola
Clear cell renal cell carcinoma (ccRCC) is the most prevalent kidney neoplasm; bone metastasis (BM) develops in 35% to 40% of metastatic patients and results in substantial morbidity and mortality, as well as medical costs. A key feature of ccRCC is the loss of function of the von Hippel–Lindau protein, which enhances angiogenesis via vascular endothelial growth factor release. Consequently, antiangiogenic tyrosine kinase inhibitors (TKI) emerged as a treatment for ccRCC. However, limited data about their efficacy in BM is available, and no systematic comparisons have been performed. We developed mouse models of bone and lung ccRCC tumors and compared their anticancer efficacy, impact on mouse survival, and mechanisms of action, including effects on tumor cells and both immune and nonimmune (blood vessels and osteoclasts) bone stromal components. This approach elucidates the efficacy of TKIs in ccRCC bone tumors to support rational interrogation and development of therapies. Significance: TKIs showed different efficacy in synchronous bone and lung metastases and did not eradicate tumors as single agents but induced extensive reprogramming of the BM microenvironment. This resulted in a significant decrease in neoangiogenic blood vessels, bone remodeling, and immune cell infiltration (including CD8 T cells) with altered spatial distribution.

13 May 2026 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
KYKai Yu
Kai Yu
JCJianfeng Chen
Jianfeng Chen
YCYu-Yi Chu
Yu-Yi Chu
SNSajith Nair
Sajith Nair
ECEmanuele Crupi
Emanuele Crupi
LWLinghua Wang
Linghua Wang
Muscle-invasive bladder cancer (MIBC) is clinically heterogeneous, and current molecular subtyping does not capture the spatial organization of tumor states and microenvironmental context. Here, we construct a spatial atlas of MIBC by integrating spatial transcriptomics from 22 tumors with matched bulk RNA and whole-exome sequencing data. We identify a continuous, spatially organized luminal-to-basal axis within individual tumors that is associated with greater chromosomal instability and transcriptional plasticity. Luminal tumor cores are enriched for FGFR3 and NECTIN4, whereas basal-like states localize toward invasive margins and are associated with elevated EGFR signaling, epithelial–mesenchymal transition, genomic instability, immune infiltration, and greater chemotherapy sensitivity. Spatial analyses further reveal lineage- and location-associated differences in tertiary lymphoid structure states. Pan-cohort analyses across over 3,000 tumors confirm conserved FGFR3–EGFR lineage exclusivity and associated immune programs. Together, these findings define a spatial framework for understanding lineage states, immune architecture, and therapeutic vulnerabilities in MIBC.

20 April 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
KYKai Yu
Kai Yu
RTRebecca Suzanne Slack Tidwell
Rebecca Suzanne Slack Tidwell
TBTharakeswara K Bathala
Tharakeswara K Bathala
RSRahul Sheth
Rahul Sheth
MKMenuka Karki
Menuka Karki
Pavlos MsaouelPavlos Msaouel
Pavlos Msaouel
Purpose: SMARCB1-deficient renal medullary carcinoma (RMC) is an aggressive kidney cancer lacking mechanism-directed therapies. We conducted a single-center, single-arm, phase II study (NCT03587662) testing the proteasome inhibitor ixazomib combined with gemcitabine and doxorubicin. Patients and Methods: Ixazomib 5.5 mg, gemcitabine 756 mg/m2, and doxorubicin 42 mg/m2 were given every 2 weeks for up to 13 cycles, followed by ixazomib plus gemcitabine maintenance. Coprimary endpoints were objective response rate (ORR) and 28-week disease-control rate (DCR) versus historic gemcitabine plus doxorubicin. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. Results: Thirty patients (median age 34.5 years old, 90% Black) were treated. The posterior ORR was 36% [95% credible interval (CrI), 21%–54%] with a 91.4% probability of exceeding historic doublet therapy. However, the 28-week DCR was 17% (95% CrI, 6%–31%), crossing the predefined futility boundary. Median PFS and OS were 3.5 and 7.4 months, respectively. Grade ≥3 toxicities were predominantly hematologic (thrombocytopenia 20%, leukopenia 17%) and manageable, with no treatment-related deaths. Single-cell and bulk multi-omics from 11 patients revealed that immune-inflamed tumors enriched for T cells and plasmacytoid/conventional dendritic cells correlated with response, whereas stromal–myeloid niches and proliferative or neuroendocrine–squamous plastic epithelial states associated with resistance. Resistant tumors upregulated unfolded protein response, proteostasis maintenance, and NF-κB pathways. Conclusions: Addition of ixazomib to gemcitabine plus doxorubicin modestly increased radiographic response but did not extend disease control in an all-comer biomarker-unstratified RMC cohort. The integrated correlatives nominate mechanisms and biomarkers to guide future mechanism–directed trials in RMC.

3 April 2025
Verified
Other
Open access
PDF file
SMStefan Maksimovic
Stefan Maksimovic
NBNina C. Boscolo
Nina C. Boscolo
LPLudovica La Posta
Ludovica La Posta
SBSergio Barrios
Sergio Barrios
Mohammad Jad MoussaMohammad Jad Moussa
Mohammad Jad Moussa
EDEleonora Dondossola
Eleonora Dondossola
In vivo efficacy of TKIs in VHL- RENCA model over 20 days. A, B) Response to TKIs in bone (A) and lung (B) tumors detected by bioluminescence, mean + SEM, n = 8 to 16/group.